Fisetin's reputation rests on a 2018 report that identified it as the most potent senolytic among flavonoids and extended lifespan in mice. In 2024 the NIA Interventions Testing Program — the multi-site, deliberately unforgiving mouse lifespan programme built precisely to catch results that do not replicate — reported that fisetin did not significantly extend lifespan at the dose and schedule tested. That is the single most important fact about fisetin and it almost never appears in the marketing.
Fisetin is a naturally occurring flavonol (a plant polyphenol) found in strawberries, apples, persimmons, onions, and other fruits and vegetables. A 2018 screen of flavonoids identified fisetin as the most potent 'senolytic' - a compound that selectively triggers death of senescent cells, damaged cells that stop dividing but persist and secrete pro-inflammatory factors termed the senescence-associated secretory phenotype (SASP). Its senolytic action is attributed to transiently disabling the anti-apoptotic survival pathways senescent cells depend on, along with prooxidant effects amplified by the copper and iron that accumulate in these cells; fisetin also has broader antioxidant and anti-inflammatory activity.
Claims below are supported by the primary sources linked under each line — the same sources we cite on the product page.
Each line pairs a claim that circulates in marketing and forums with the trial result that contradicts or narrows it.
Quotations are verbatim from the cited paper. Negative and inconclusive trials are listed alongside the positive ones because that is the whole point of this page.
“The NIA Interventions Testing Program's rigorous multi-site mouse lifespan study found fisetin did not significantly extend lifespan at the dose and schedule tested - a key non-replication of the 2018 lifespan finding.”
“In a double-blind RCT of 37 colorectal cancer patients on chemotherapy, fisetin 100 mg/day for 7 weeks significantly lowered plasma IL-8 and hs-CRP versus placebo.”
“We found that fisetin mitigated the adverse changes in frailty and grip strength with aging. Fisetin had no effects in young mice.”
“Promising results with neuroprotective effects of senotherapeutic agents such as quercetin, resveratrol, Epigallocatechin-gallate, curcumin and fisetin were reported from preclinical studies. However, in-human trials remain limited, and findings were inconclusive.”
“We are conducting a multi-center, randomized, double-blinded, adaptive allocation phase 2 clinical trial to assess the efficacy of the senolytic drug fisetin in preventing clinical deterioration of elderly patients diagnosed with sepsis.”
Because senescent cells accumulate with age and contribute to frailty, vascular dysfunction, inflammation, and multiple age-related diseases, selectively clearing them is a leading longevity strategy. In aged mice, intermittent fisetin has reduced senescence markers and improved endothelial function, arterial stiffness, muscle grip strength, and glucose metabolism, and one landmark 2018 study reported extended median and maximum lifespan - though the NIA Interventions Testing Program later found no significant lifespan extension at the dose and schedule it tested, so that flagship result appears dose- and schedule-dependent at best. Human evidence is early: small randomized trials show anti-inflammatory effects (100 mg/day lowered IL-8 and hs-CRP in colorectal cancer patients on chemotherapy) and better outcomes when added to stroke thrombolysis, but no published trial has demonstrated senescent-cell clearance or aging benefits in healthy older adults, and larger trials (in childhood-cancer survivors, frailty, and sepsis) are still underway. Reviewers caution that senolytics should not yet be used outside clinical trials. This evidence describes the fisetin compound and the senolytic/senescent-cell-clearance mechanism itself, not this specific commercial product.
A grade that cannot be falsified is a marketing claim. These are the specific results that would move this one up.
Fisetin is inexpensive and the preclinical case is one of the better ones in this field, which is why we grade it Emerging rather than Preliminary. If you take it, take it as an experiment you are running on yourself rather than as a therapy, understand that the lifespan claim failed its most rigorous animal test, and do not let it displace the interventions that already have human outcome evidence.
Where every senolytic candidate actually stands, including the ones with completed human trials.
The human readouts, reported without the framing the field's press releases use.
Graded Strong for muscle and physical function — the outcome the mouse fisetin work moved, with human evidence behind it.
Graded Strong for falls and mobility. Frailty is the endpoint fisetin improved in mice, and this is what moves it in people.
Fisetin molecule page · Cellular senescence · Quercetin · Senolytics · Fisetin capsules: the early evidence · Fisetin from food: strawberry and red onion salad · The full evidence record
Sibling pages in this record: NMN (nicotinamide mononucleotide) · Resveratrol · Vitamin D · Omega-3 fish oil
The ITP is an NIA-funded programme that tests candidate longevity compounds for lifespan effects in genetically heterogeneous mice, at multiple independent sites, with blinding and pre-registered protocols. It exists because single-laboratory lifespan results have a poor replication record. When the ITP reports that a compound did not extend lifespan at the dose and schedule tested, that is the strongest available evidence against the animal lifespan claim.
No. Fisetin remains one of only two natural compounds that meet rigorous senolytic criteria, it improved arterial function and frailty measures in old mice, and one small randomized human trial showed reduced IL-8 and hs-CRP. What it means is that the specific claim 'fisetin extends lifespan' failed the best test anyone has run.
It is extrapolated from mouse dosing, not from a human trial. The published human data used 100 mg/day continuously in a disease population. There is no established human senolytic protocol, and anyone presenting one as settled is going beyond the record.
Because the mechanism is unusually well characterised and there is early human data, which is exactly our definition of Emerging: plausible mechanism, early human evidence, small or short or not yet replicated. The grade note on the product page has said anti-aging use remains speculative since it was written.